Mostrar el registro sencillo del ítem

dc.contributor.authorBleriot, Ines
dc.contributor.authorBlasco, Lucia
dc.contributor.authorPacios, Olga
dc.contributor.authorFernández-García, Laura
dc.contributor.authorAmbroa, Antón
dc.contributor.authorLópez, María
dc.contributor.authorOrtiz-Cartagena, Concha
dc.contributor.authorCuenca, Felipe Fernández
dc.contributor.authorOteo-Iglesias, Jesus 
dc.contributor.authorPascual, Álvaro
dc.contributor.authorMartínez-Martínez, Luis
dc.contributor.authorDomingo-Calap, Pilar
dc.contributor.authorWood, Thomas K
dc.contributor.authorTomás, María
dc.contributor.authorWood, Thomas K.
dc.date.accessioned2022-05-24T07:09:05Z
dc.date.available2022-05-24T07:09:05Z
dc.date.issued2022-03-16
dc.identifier.citationSci Rep. 2022 Mar 16;12(1):4488.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/14469
dc.description.abstractSince their discovery, toxin-antitoxin (TA) systems have captivated the attention of many scientists. Recent studies have demonstrated that TA systems play a key role in phage inhibition. The aim of the present study was to investigate the role of the PemIK (PemK/PemI) type II TA system in phage inhibition by its intrinsic expression in clinical strains of Klebsiella pneumoniae carrying the lncL plasmid, which harbours the carbapenemase OXA-48 and the PemK/PemI TA system. Furthermore, induced expression of the system in an IPTG-inducible plasmid in a reference strain of K. pneumoniae ATCC10031 was also studied. The results showed that induced expression of the whole TA system did not inhibit phage infection, whereas overexpression of the pemK toxin prevented early infection. To investigate the molecular mechanism involved in the PemK toxin-mediated inhibition of phage infection, assays measuring metabolic activity and viability were performed, revealing that overexpression of the PemK toxin led to dormancy of the bacteria. Thus, we demonstrate that the PemK/PemI TA system plays a role in phage infection and that the action of the free toxin induces a dormant state in the cells, resulting in inhibition of phage infections.es_ES
dc.description.sponsorshipThis study was funded by grant PI19/00878 awarded to M. Tomás within the State Plan for R+D+I 2013-2016 (National Plan for Scientific Research, Technological Development and Innovation 2008-2011) and co-financed by the ISCIII-Deputy General Directorate for Evaluation and Promotion of Research—European Regional Development Fund "A way of Making Europe" and Instituto de Salud Carlos III FEDER, Spanish Network for the Research in Infectious Diseases (REIPI, RD16/0016/0001, RD16/0016/0006 and RD16/CIII/0004/0002) and by the Study Group on Mechanisms of Action and Resistance to Antimicrobials, GEMARA (SEIMC, http://www.seimc.org/). M. Tomás was financially supported by the Miguel Servet Research Programme (SERGAS and ISCIII). I. Bleriot was financially supported by pFIS program (ISCIII, FI20/00302). O. Pacios and M. López was financially supported by a grant IN606A-2020/035 and IN606B-2018/008, respectively (GAIN, Xunta de Galicia) and M. Gonzalez-Bardanca was financially supported by the Rio Hortega program (ISCIII, CM20/00198).es_ES
dc.language.isoenges_ES
dc.publisherNature Publishing Group es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectDevelopmental biologyes_ES
dc.subjectMicrobiologyes_ES
dc.subjectMolecular biologyes_ES
dc.subjectMolecular medicinees_ES
dc.titleThe role of PemIK (PemK/PemI) type II TA system from Klebsiella pneumoniae clinical strains in lytic phage infectiones_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID35296704es_ES
dc.format.volume12es_ES
dc.format.number1es_ES
dc.format.page4488es_ES
dc.identifier.doi10.1038/s41598-022-08111-5es_ES
dc.contributor.funderInstituto de Salud Carlos III es_ES
dc.contributor.funderPlan Nacional de I+D+i (España) es_ES
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) es_ES
dc.contributor.funderRETICS-Investigación en Patología Infecciosa (REIPI-ISCIII) (España) es_ES
dc.contributor.funderSociedad Española de Enfermedades Infecciosas y Microbiología Clínica es_ES
dc.contributor.funderXunta de Galicia (España) es_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn2045-2322es_ES
dc.relation.publisherversionhttps://doi.org/10.1038/s41598-022-08111-5es_ES
dc.identifier.journalScientific Reportses_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/MINECO//RD16%2F0016%2F0001/ES/RED ESPAÑOLA DE INVESTIGACIÓN EN PATOLOGÍAS INFECCIOSAS/ es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/MINECO//RD16%2F0016%2F0006/ES/RED ESPAÑOLA DE INVESTIGACIÓN EN PATOLOGÍAS INFECCIOSAS/ es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/RD16/CIII/0004/0002es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/FI20/00302es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/CM20/00198es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/PI19/00878es_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución 4.0 Internacional